Recent Research Analysts’ Ratings Updates for Alkermes (ALKS)

Several brokerages have updated their recommendations and price targets on shares of Alkermes (NASDAQ: ALKS) in the last few weeks:

• 5/13/2026 – Alkermes had its price target raised by Robert W. Baird from $45.00 to $48.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Alkermes was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/6/2026 – Alkermes had its price target raised by UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Wells Fargo & Company from $43.00 to $44.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Needham & Company LLC from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Alkermes was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 4/27/2026 – Alkermes was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/9/2026 – Alkermes had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a “neutral” rating on the stock.

Insider Activity

In other news, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $33.20, for a total transaction of $67,528.80. Following the sale, the executive vice president owned 231,558 shares in the company, valued at approximately $7,687,725.60. The trade was a 0.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $33.40, for a total transaction of $300,600.00. Following the sale, the executive vice president owned 81,389 shares in the company, valued at approximately $2,718,392.60. This trade represents a 9.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 39,102 shares of company stock worth $1,265,090. Corporate insiders own 4.59% of the company’s stock.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.